Barbell Medicine Podcast

Barbell Medicine

Podcast by Barbell Medicine

  1. Episode #380: The Peptide Market Audit: Injury Healing or Biohacking Hype?

    5D AGO

    Episode #380: The Peptide Market Audit: Injury Healing or Biohacking Hype?

    Biohackers and longevity clinics claim peptides are a side-effect-free sniper rifle for fat loss and injury recovery, but the reality is often buried in failed clinical trials and regulatory bans. Many popular compounds like BPC-157 have never undergone a single randomized controlled trial in humans, despite their reputation for Wolverine-like healing. This episode dismantles the hype surrounding the gray market, exposing the significant risks of immunogenicity and heavy metal contamination. Learn why modern load management and evidence-based medicine beat a research chemical bought with Bitcoin every time. Next Steps For evidence-based resistance training programs: barbellmedicine.com/training-programs For individualized medical and training consultation: barbellmedicine.com/coaching Explore our full library of articles on health and performance: barbellmedicine.com/resources To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/ Key Points The FDA Category 2 Crackdown: Federal regulators restricted many peptides because of the risk of immunogenicity where the body creates antibodies that attack its own proteins.BPC-157 Has Zero Human Data: Despite being marketed for tendon repair, there is not a single published human randomized controlled trial for this molecule.The MK-677 Prediabetes Tax: While it increases lean mass, human trials show zero improvement in strength or power while frequently causing insulin resistance.Retatrutide as the Weight Loss Godzilla: This triple agonist is achieving nearly 29 percent weight loss in trials by increasing energy expenditure through thermogenesis.Sourcing and Safety Realities: A study of 44 research chemicals found that only 18 actually contained the labeled compound, with many containing heavy metals.The 40-Amino-Acid Rule: The legal distinction between a peptide and a protein is based on size, which dictates how the FDA regulates these substances and how your body absorbs them.  Timestamps 00:03 Intro: The CJC-1295 Heart Attack Case05:39 Defining a Peptide: The 40-Amino-Acid Bright Line15:14 GH Secretagogues: CJC-1295 and Ipamorelin23:51 MK-677: The Oral Hunger Mimetic and Prediabetes Risk32:56 BPC-157 and the Lack of Human Data38:12 Immunogenicity: Why the FDA Banned BPC-15749:46 Retatrutide: The Triple Agonist Weight Loss Godzilla01:11:24 Summary: Peptides vs. Anabolic Steroids01:16:12 The Sourcing Spectrum: Pharmaceutical vs. Research Chemicals Clinical Pearls Use load management and progressive resistance training as the primary intervention for tendon and muscle injuries rather than unproven peptides.If choosing to use metabolic modulators, monitor fasting blood glucose and insulin sensitivity to avoid drug-induced prediabetes or metabolic dysfunction.Avoid the research chemical gray market entirely due to the high prevalence of under-dosing, contamination, and incorrect active ingredients found in third-party testing.Resources https://pubmed.ncbi.nlm.nih.gov/16352683/https://pubmed.ncbi.nlm.nih.gov/18347346/https://pmc.ncbi.nlm.nih.gov/articles/PMC2657499/https://pubmed.ncbi.nlm.nih.gov/9849822/https://pubmed.ncbi.nlm.nih.gov/10496658/https://pubmed.ncbi.nlm.nih.gov/21298258/https://pubmed.ncbi.nlm.nih.gov/18981485/https://pubmed.ncbi.nlm.nih.gov/9467542/https://pubmed.ncbi.nlm.nih.gov/18981485/https://pubmed.ncbi.nlm.nih.gov/20554713/https://pubmed.ncbi.nlm.nih.gov/39813152/Duzel 2007Strinic 2017Sikiric 1993 He 2022https://pmc.ncbi.nlm.nih.gov/articles/PMC2289708/https://pubmed.ncbi.nlm.nih.gov/10469335/https://pubmed.ncbi.nlm.nih.gov/23050815/https://pubmed.ncbi.nlm.nih.gov/20536454/https://pubmed.ncbi.nlm.nih.gov/29986520/https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/https://pubmed.ncbi.nlm.nih.gov/41090431/https://pubmed.ncbi.nlm.nih.gov/38858523/https://pubmed.ncbi.nlm.nih.gov/20445536/https://pmc.ncbi.nlm.nih.gov/articles/PMC3136748/#R41https://pubmed.ncbi.nlm.nih.gov/25738459/https://pubmed.ncbi.nlm.nih.gov/33473109/https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/ https://pubmed.ncbi.nlm.nih.gov/31599840/https://pubmed.ncbi.nlm.nih.gov/18206919/https://pmc.ncbi.nlm.nih.gov/articles/PMC5820696/ Our Sponsors: * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com * Check out Factor: https://factormeals.com/bbm50off * Check out Quince: https://quince.com/BBM * Check out Rosetta Stone and use my code TODAY for a great deal: https://www.rosettastone.com Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    1h 22m
  2. Ozempic & Alcohol, The Trap Bar Myth, and A Medical Mystery | Barbell Medicine AMA Teaser

    DEC 23

    Ozempic & Alcohol, The Trap Bar Myth, and A Medical Mystery | Barbell Medicine AMA Teaser

    Experiencing a pins-and-needles sensation on a run or fearing the straight bar deadlift shouldn't be your fitness journey's bingo card. Many trainees abandon effective habits due to false narratives regarding physiological signals or myths regarding back safety. We break down the clinical reality of exercise-induced sensations, the ethics of modern metabolic medicine, and why your choice of imlpement is more about preference than peril. Resources and Next Steps For evidence-based resistance training programs: barbellmedicine.com/training-programs For individualized medical and training consultation: barbellmedicine.com/coaching Explore our full library of articles on health and performance: barbellmedicine.com/resources To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/ Topics The Hemodynamic Itch: Why vasodilation and increased blood flow to capillaries can cause mechanical stimulation of nerve endings during a run.Exercise-Induced Anaphylaxis: The critical difference between benign "runner’s itch" and a systemic medical emergency involving hives and hemodynamic instability.Medical Paternalism: Why withholding GLP-1 medications from patients who drink alcohol is a flawed clinical approach that ignores aggregate health risk reduction.The Seatbelt Analogy: Treating one health risk (obesity) is objectively better than leaving it untreated, even if other risks (alcohol) remain constant.The EMG Trap: Why electrical muscle activity data is a poor predictor of long-term strength and hypertrophy outcomes compared to longitudinal studies.Biomechanical Distribution: How the trap bar shifts load toward the quadriceps while the straight bar emphasizes the hamstrings and erectors without changing "safety." Clinical Pearls Identify Red Flags: If itching is accompanied by wheezing, nausea, or dizziness, stop exercise immediately and seek emergency medical care.Prioritize Habituation: For benign runner’s itch, consistent training typically leads to physiological adaptation and symptom resolution within a few weeks.Shared Decision-Making: When choosing between deadlift variations, select the tool that aligns with your specific goals—use the straight bar for powerlifting prep and the trap bar for general strength or power development. Timestamps00:00 – Intro to the Direct Line AMA series00:43 – The Mystery of "Runner’s Itch": Mechanisms and Hemodynamics04:19 – Case Study: 24-year-old Marine and Exercise-Induced Anaphylaxis06:22 – Summary: Benign Itching vs. Cholinergic Urticaria vs. Anaphylaxis07:24 – GLP-1 Receptor Agonists and Heavy Alcohol Use10:57 – Beyond the Stomach: How GLP-1s Impact Brain Reward Pathways15:32 – Avoiding Paternalism in Medicine: Shared Decision-Making18:12 – The Great Deadlift Debate: Trap Bar vs. Straight Bar21:31 – Why EMG Data is Often Misleading for Trainees24:54 – Debunking the "Save Your Back" Myth Our Sponsors: * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com * Check out Factor: https://factormeals.com/bbm50off * Check out Quince: https://quince.com/BBM * Check out Rosetta Stone and use my code TODAY for a great deal: https://www.rosettastone.com Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    31 min
  3. Episode 379: Menopause Myths, Cortisol Belly, & The Truth About IUDs

    DEC 16

    Episode 379: Menopause Myths, Cortisol Belly, & The Truth About IUDs

    The wellness industry wants you to believe that menopause renders you fragile, fasting creates "cortisol belly," and birth control is silently destroying your skeletal health. These claims aren't just scientifically inaccurate; they act as "nocebo" barriers that scare women away from effective training and healthcare. We brought in the heavy artillery—Dr. Lauren Colenso-Semple, Dr. Loraine Baraki, and Dr. Spencer Nadolsky—to dissect the physiology behind these viral fears. Discover why your body remains resilient through hormonal transitions and why lifestyle or GLP-1s is a false dichotomy,  Dr. Colenso-Semple: @drlaurencs1Dr. Loraine Baraki: @loraine_barbellmedicineDr. Spencer Nadolsky: @drnadolsky Key Learning Points The Menopause "Cliff" Myth: Menopause does not destroy your ability to recover or adapt to exercise.1 While aging may require programming adjustments, your muscles do not stop responding to tension and progressive overload simply because estrogen levels change. Cortisol Fear-mongering: There is no evidence that intermittent fasting or skipping breakfast causes pathological "cortisol belly" or visceral fat storage in women. Fasting is simply a tool for Calorie restriction, not a hormonal wrecking ball. IUDs & Bone Density: Levonorgestrel IUDs (hormonal) work primarily via local action on the uterus, not systemic suppression. Contrary to viral claims, they do not "eat your bones," and most users continue to ovulate and produce protective estrogen. The "Masking" Fallacy: Amenorrhea (lack of period) on an IUD is a known, harmless side effect of a thinned uterine lining. It is rarely "masking" a dangerous underlying condition like premature ovarian insufficiency. Birth Control & Performance: Population-level data shows that hormonal contraceptives do not clinically impair strength or athletic performance. While they increase SHBG and lower free testosterone, women are not "little men" dependent solely on testosterone for performance. GLP-1 Agonists (Ozempic/Mounjaro): Using medication to treat the appetite dysregulation of obesity is not "cheating." Muscle loss on these drugs is primarily a function of the Caloric deficit, not the drug itself, and can be mitigated with resistance training. Get More Value: Exclusive Content and Resources Want to support the show and get early, ad-free access to all episodes plus exclusive bonus content? Subscribe to Barbell Medicine Plus and get ad-free listening, product discounts, and more. Try it free for 30-days. Unsure which training plan is right for you? Take the free Barbell Medicine Template Quiz to be matched with the ideal program for your goals and experience level. For media, support, or general questions, please contact us at support@barbellmedicine.com Clinical Pearls & Takeaways Programming for Menopause: Stop treating menopause as a disability. Continue to lift heavy (RPE 6-9) and perform conditioning. If recovery lags, adjust volume (sets/reps) before blaming hormones. Protein Simplified: Ignore the complex "ideal body weight" math. Aim for ~1.6g/kg of total body weight, or simply add one extra serving of protein (like a shake) to your current daily intake. Medical Decisions: Do not remove an IUD or avoid birth control solely due to social media fear-mongering about bone density or "low T." These choices should be based on your contraceptive needs and symptom management (e.g., PCOS, endometriosis). Timestamps 00:00 Intro: The "Fragile Female" Narrative01:00 Does Menopause Destroy Recovery?11:00 Muscle Fiber Types: Fact vs. Fiction24:00 Fasting, "Cortisol Belly," and Visceral Fat34:00 Protein Intake: Survival vs. Optimal41:40 Dr. Lorraine Baraki: Do IUDs Cause Bone Loss?50:00 Birth Control, Acne, and Athletic Performance59:00 Dr. Spencer Nadolsky: The Truth About GLP-1s & Muscle Loss01:05:00 Final Verdict: You Are Not Fragile References Thomas, Ewan et al. “The effect of resistance training programs on lean body mass in postmenopausal and elderly women: a meta-analysis of observational studies.” Aging clinical and experimental research vol. 33,11 (2021): 2941-2952. doi:10.1007/s40520-021-01853-8 TWORoberts, Brandon M et al. “Sex Differences in Resistance Training: A Systematic Review and Meta-Analysis.” Journal of strength and conditioning research vol. 34,5 (2020): 1448-1460. doi:10.1519/JSC.0000000000003521Khalafi, Mousa et al. “The effects of exercise training on body composition in postmenopausal women: a systematic review and meta-analysis.” Frontiers in endocrinology vol. 14 1183765. 14 Jun. 2023, doi:10.3389/fendo.2023.1183765Staron, R S et al. “Fiber type composition of the vastus lateralis muscle of young men and women.” The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society vol. 48,5 (2000): 623-9. doi:10.1177/002215540004800506 Hunter, Sandra K. “The Relevance of Sex Differences in Performance Fatigability.” Medicine and science in sports and exercise vol. 48,11 (2016): 2247-2256. doi:10.1249/MSS.0000000000000928Nuzzo, James L. “Narrative Review of Sex Differences in Muscle Strength, Endurance, Activation, Size, Fiber Type, and Strength Training Participation Rates, Preferences, Motivations, Injuries, and Neuromuscular Adaptations.” Journal of strength and conditioning research vol. 37,2 (2023): 494-536. doi:10.1519/JSC.0000000000004329Verdell, J. Tyler MD; Acker, Matthew MD. Does the LNG-IUD decrease BMD in adolescent females?. Evidence-Based Practice 23(4):p 10-11, April 2020. | DOI: 10.1097/EBP.0000000000000601Jäger, Ralf et al. “International Society of Sports Nutrition Position Stand: protein and exercise.” Journal of the International Society of Sports Nutrition vol. 14 20. 20 Jun. 2017, doi:10.1186/s12970-017-0177-8Tan, Yimei et al. “Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.” Acta diabetologica vol. 62,5 (2025): 589-606. doi:10.1007/s00592-025-02468-5 Our Sponsors: * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com * Check out Factor: https://factormeals.com/bbm50off * Check out Quince: https://quince.com/BBM * Check out Rosetta Stone and use my code TODAY for a great deal: https://www.rosettastone.com Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    1h 6m
  4. Episode #378: Bulletproof or Broken- Why 'Perfect Form' Is a Lie

    DEC 8

    Episode #378: Bulletproof or Broken- Why 'Perfect Form' Is a Lie

    Bulletproof or Broken- Why 'Perfect Form' Is a Lie Episode SummaryIn this comprehensive episode, we dismantle the pervasive myth that the human body is a fragile machine susceptible to catastrophic injury from minor technique flaws. This narrative, often perpetuated by social media influencers screaming "Snap City," creates widespread fear avoidance behavior (kinesiophobia) that does more harm than good. By reviewing extensive epidemiological data, we demonstrate that obsessing over "perfect" technique has virtually zero correlation with injury risk. Instead, we explore the true drivers of pain and injury: improper load management (doing too much, too fast) and hyper-specialization (lack of movement variability). We also introduce the REP Model (Repeatable, Efficient, Points of Performance) as a practical compass for movement and provide a new framework for staying healthy: focus on robustness and managing your training dose, not fear-based mechanics. Timestamps 00:00:00 - The Fragility Myth: The Body-as-a-Car Metaphor and the Nocebo Effect.00:11:31 - Defining Injury: Why the scientific data is a methodological mess.00:21:46 - Injury Rates Compared: The Gym vs. Running vs. Contact Sports.00:33:32 - MRI is a Liar: Understanding asymptomatic abnormalities ("wrinkles on the inside").00:39:10 - The Body-as-a-Bank-Account: A better analogy for capacity and load.00:41:59 - Suspect 1: Heavy Weight. (Verdict: Innocent).00:45:44 - Suspect 2: Orthopedic Cost & Exercise Selection. (Verdict: Innocent).00:49:53 - Suspect 3: Hyper-Specialization. (Verdict: Guilty).00:54:23 - Suspect 4: Movement Speed. (Verdict: Innocent).00:57:21 - Suspect 5: Age. (Verdict: Innocent - The "Old Man Strength" phenomenon).01:02:17 - Suspect 6: Anabolic Steroids. (Verdict: Guilty-ish).01:04:38 - Suspect 7: Accidents & Gravity Events. (Verdict: Guilty).01:08:22 - The Myth of the "Robotic" Elite Lifter: Why variability is a feature, not a bug.01:15:48 - The REP Model: A new framework for technique (Repeatable, Efficient, Points of Performance).01:20:01 - Conclusion: Your marching orders. ⭐ Get More Value: Exclusive Content and Resources Want to support the show and get early, ad-free access to all episodes plus exclusive bonus content? Subscribe to Barbell Medicine Plus and get ad-free listening, product discounts, and more. Try it free for 30-days. Unsure which training plan is right for you? Take the free Barbell Medicine Template Quiz to be matched with the ideal program for your goals and experience level. For media, support, or general questions, please contact us at support@barbellmedicine.com Action plan : https://www.barbellmedicine.com/injury-risk-action-plan/ I. The Fragility Myth: Why You Are Not a CarThe fitness industry has long relied on the "body-as-a-machine" metaphor to explain pain. The logic suggests that if your alignment is off—much like a car with bad wheel alignment—your parts will wear out and fail. This has led to a culture of fear where athletes spend 30 minutes warming up rotator cuffs or obsessing over a single degree of spinal flexion during a deadlift. However, this mechanical model is fundamentally flawed. Unlike a car, human tissues are adaptable. The Brake Pad vs. The Callus: If you drive a car daily, the brake pads get thinner until they break. If you expose your skin to a barbell daily, it doesn't wear away; it builds a callus. Wolf’s Law & Davis’ Law: Bones get denser, and tendons/ligaments thicken when exposed to appropriate stress. The Nocebo Effect The greatest risk in the gym isn’t a rounded back; it’s the nocebo effect. This is the phenomenon where negative expectations or beliefs lead to negative outcomes. When influencers draw red lines on videos and catastrophize movement, they are socially transmitting pain and fear. This "socially transmitted kinesiophobia" convinces you that you are fragile, leading to hyper-vigilance and, ironically, a higher sensation of pain. Key Takeaway: You do not need to be fixed. You are robust and adaptable. The industry profits from your fragility, but the science supports your resilience. II. The Data Hierarchy of Risk To understand the true risk of the gym, we must look at the epidemiology of injury. Unfortunately, the scientific community struggles to agree on a definition of "injury." Some studies count a stubbed toe, while others only count surgery. Despite this methodological mess, the trends in the data are clear: The gym is one of the safest places to be. Injury Rates by Activity (Per 1,000 Hours) Bodybuilding: 0.2 – 1.0Powerlifting / Weightlifting: 1.0 – 4.0Running: ~10 (Novices up to ~18)Field Sports (Soccer, Rugby): 15 – 80+Motocross: >90 The perception that lifting heavy weights is dangerous while recreational sports are "safe fun" is backward. The gym is a controlled environment where you dictate the load, tempo, and rest. In contrast, field sports are chaotic, "dirty" environments with high impact forces and unpredictable variables. MRI is a Liar: The "Wrinkles on the Inside" Modern medicine often over-relies on imaging. Studies on asymptomatic populations (people with no pain) show: High rates of disc bulges and degeneration in healthy adults. "Abnormalities" in 100% of elite baseball pitchers' shoulders. These findings are often adaptations, not pathologies. Just as you get wrinkles on your skin as you age, you get "wrinkles" on your spine. Treating an MRI finding rather than the person leads to unnecessary fear and medical interventions. III. The True Culprit: Load Management If technique isn't the primary driver of injury, what is? The answer lies in the balance between Load and Capacity. Think of your body as a Bank Account: Capacity: The funds you have in the bank ($1,000).Load: The withdrawal you are trying to make ($1,200).Injury/Pain: The overdraft fee. Pain occurs when the training load exceeds your current tissue capacity. The form police believe the overdraft happened because you swiped the debit card with your left hand (technique). In reality, the overdraft happened because you spent too much money. The Lineup of Suspects: Who is Guilty?We analyzed the common scapegoats for gym injuries to determine their actual guilt based on the evidence. Suspect: Heavy WeightVerdict: Innocent. Powerlifters (high load) have similar or lower injury rates than runners (low load).Suspect: Orthopedic Cost / Exercise SelectionVerdict: Innocent. Squats and deadlifts are not "expensive" to joints; they are investments that build bone density and tissue strength.Suspect: Hyper-SpecializationVerdict: Guilty. Doing the exact same movement pattern (same stance, same tempo, same shoe) for years creates overuse issues. Variation "rotates the tires" and spreads stress across tissues.Suspect: Movement SpeedVerdict: Innocent. Olympic weightlifting (high velocity) is as safe as powerlifting. It comes down to preparation, not speed.Suspect: AgeVerdict: Innocent (Inverse Trend). Older lifters tend to have lower injury rates than younger lifters, likely due to "old man strength" (accumulated capacity), better autoregulation, and less ego-lifting.Suspect: Anabolic SteroidsVerdict: Guilty-ish. Steroids allow muscles to adapt faster than tendons and ligaments, creating a "Ferrari engine in a Honda Civic" mismatch.Suspect: Accidents (Gravity Events)Verdict: Guilty. A significant portion of gym injuries are simply dropping weights on toes or tripping. IV. Technique: The Compass, Not the Rulebook We have been taught that elite lifters move like robots—that every rep is identical. However, motion capture data reveals that elite athletes exhibit significant movement variability (motor noise) from rep to rep. This variability is a feature, not a bug; it allows the biological system to solve the problem of "lifting the weight" in real-time. Instead of forcing your body into a rigid, robotic ideal, we utilize the REP Model as a compass for technique. The REP Model R - Repeatable: Can you perform the movement with relatively consistent range of motion and patterns? (Your squat should look like a squat, not a Good Morning).E - Efficient: Does the movement solve the problem with the least wasted energy? (e.g., keeping the bar close in a deadlift).P - Points of Performance: Does it meet the specific constraints of your goal? (e.g., squatting below parallel for powerlifting standards). If your lift meets these criteria, your technique is likely safe and effective. You do not need a "neutral spine" to be safe—in fact, keeping a truly neutral spine during a heavy deadlift is anatomically impossible. V. Actionable Takeaways It is time to stop playing defense with your training and start playing offense. Stop optimizing for "safety" by avoiding exercises. You are safer in the squat rack than almost anywhere else. Use a wide variety of exercises to build a broad base of capacity.Abandon the Robotic Mindset. Use the REP Model. If the lift is repeatable, efficient, and meets your goals, stop obsessing over millimeter deviations.Manage the Dose. This is the single most important variable for health. Most injuries are "too much, too soon." Keep the majority of your training in the RPE 6–8 range. Build the callus; don't rub until you get a blister. References Aagaard, P., et al. (1996). Neural adaptation to resistance training: changes in evoked V-wave and H-reflex responses. Journal of Applied Physiology. Aasa, U., et al. (2017). Injuries among weightlifters and powerlifters: a systematic review. British Journal of Sports Medicine. Aasa, U. (2019). (Likely referring to a follow-up study or commentary on powerlifting injuries, e.g., Preventing injuries in weightlifting and powerlifting). Bahr, R. (2009). No injuries, but plenty of pain? On the methodology for recording overuse symptoms in sports. British Journal of Sports Medicine. Bahr, R., et al. (2011). Inte

    1h 23m
  5. Episode 377: GLP-1 Anti-Obesity Medications Update-Efficacy, Muscle Risk, and Future

    DEC 2

    Episode 377: GLP-1 Anti-Obesity Medications Update-Efficacy, Muscle Risk, and Future

    Episode Summary: The Cardiometabolic Revolution of Semaglutide, Tirzepatide, and Beyond This episode provides a comprehensive, evidence-based update on GLP-1 receptor agonists (anti-obesity medications), featuring Dr. Jordan Feigenbaum, Dr. Austin Baraki, and Dr. Spencer Nadolsky. The hosts review the rapid evolution of these drugs—from short-acting injectables to potent multi-agonists like Tirzepatide (Mounjaro/Zepbound) and Retatrutide—which now achieve weight loss efficacy rivaling bariatric surgery. The discussion clarifies the broad, weight-independent benefits these drugs offer for cardiovascular, renal, and liver health (CKM Syndrome). The experts address common concerns, including the high incidence of gastrointestinal side effects and the heavily debated risk of muscle mass loss, concluding the risk is often overblown and easily mitigated by resistance training and adequate protein intake. Finally, they discuss the biggest hurdle to access: cost, and the role of newer oral and compounded options in the evolving landscape. ⏱️ Episode Timestamps 00:00 Welcome and Introductions00:05:48 Defining GLP-1 and the Incretin Effect00:08:06 Debunking "Nature's Ozempic" (DPP-4 resistance)00:11:17 Evolution of GLP-1 Drugs (Longer duration, higher potency)00:14:35 Defining and Discussing "Food Noise"00:19:43 Semaglutide Efficacy (STEP & SUSTAIN Trials)00:22:36 Tirzepatide Efficacy (SURMOUNT Trials)00:24:50 Triple Agonist Pipeline (Retatrutide)00:28:04 Oral Options and Future Accessibility (Orforglipron)00:33:10 Weight-Independent Cardio Benefits (SELECT Trial)00:38:12 Benefits for Kidney and Liver Health (CKM Syndrome)00:41:47 Emerging Benefits (Sleep Apnea, Addiction, Cancer)00:48:20 Common Side Effects (Nausea, Constipation, Fatigue)00:52:59 Rare/Serious Risks (Pancreatitis, NAION)00:58:36 Muscle Mass Loss Concern (Hype vs. Data)01:13:44 Biggest Hurdle: Cost and Prior Authorization01:16:50 Compounded Versions vs. Research Chemicals01:19:57 Role of Older Anti-Obesity Medications and Microdosing01:24:41 Final Summary 🔗 Resources and Next Steps Work with Experts on Cardiometabolic Health: Connect with Dr. Austin Baraki and Dr. Spencer Nadolsky: https://joinvineyard.com/  For evidence-based resistance training programs: barbellmedicine.com/training-programs For individualized medical and training consultation: barbellmedicine.com/coaching Explore our full library of articles on health and performance: barbellmedicine.com/resources To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/ I. Basic Science and The Evolution of Anti-Obesity Medication Defining GLP-1 and the Incretin Effect GLP-1 (Glucagon-like peptide 1) is a naturally occurring peptide hormone released by the intestines after food ingestion.1 It plays a role in the incretin effect, which enhances insulin secretion from the pancreas.2 However, natural GLP-1 is quickly broken down by the DPP-4 enzyme, limiting its efficacy.3 Modern GLP-1 receptor agonists (like Semaglutide and Tirzepatide) are synthetic analogs engineered to be resistant to DPP-4 breakdown, allowing them to stick around longer and reach receptors in the brain to modulate appetite. The concept of food noise describes the persistent, relentless, non-hunger-related thoughts about food that many individuals with obesity experience.5 Patients often report that the cessation of this food noise is one of the most profound effects of the medication, freeing up cognitive energy previously dedicated to ruminating over food. The Rapidly Advancing Pipeline The evolution of this drug class has been defined by three trends: Duration: Moving from twice-daily injections (Exenatide) to weekly injections (Ozempic) and future monthly options.Potency: Increasing efficacy through molecular engineering and multi-agonist targeting (e.g., Tirzepatide hitting GLP-1 and GIP receptors).7Tolerability: Improving the side effect profile, making newer agents easier to tolerate. Upcoming agents include oral options like Orforglipron and high-dose oral Semaglutide, which promise easier administration and potentially lower costs.8 Triple agonists like Retatrutide are showing efficacy in the mid-20% total weight loss range, rivaling metabolic surgery outcomes. II. Efficacy and Broad Health Benefits Weight Loss Efficacy The clinical data demonstrates significant efficacy, classifying these drugs as game-changers: Semaglutide (Ozempic/Wegovy): Averages around 15% total body weight loss.10Tirzepatide (Mounjaro/Zepbound): Averages 20-21% total body weight loss, generally showing superiority and improved tolerability compared to Semaglutide.11Pipeline Agents (Retatrutide): Showing potential for 24-25% total weight loss, pushing pharmacological intervention into the same league as bariatric surgery. Weight-Independent Organ Protection (CKM Syndrome) A significant portion of the benefit derived from these medications is weight-independent, meaning it's separate from the mass lost.12 The drugs exert pleiotropic (multiple) effects across organ systems, leading to the coining of CKM Syndrome (Cardiovascular-Kidney-Metabolic Syndrome). Cardiovascular Health: The SELECT trial demonstrated a radical reduction in Major Adverse Cardiovascular Events (MACE), with evidence suggesting at least two-thirds of this benefit is independent of the weight lost.Renal and Liver Health: Trials like FLOW are demonstrating benefits for Chronic Kidney Disease (CKD) progression.14 Furthermore, resolution or significant improvement of Fatty Liver Disease is commonly observed once weight loss exceeds the 7.5-10% threshold. Emerging and Future Benefits Research is exploring the impact of GLP-1 agonists on: Obstructive Sleep Apnea (OSA): Leading to resolution or reduction in severity, confirmed in trials.Addiction: Early anecdotal and some retrospective data show reduced alcohol consumption, with potential benefits being explored for gambling and opioid addiction due to strong effects in the brain's reward center.Neuroprotection and Cancer: The potential for favorable effects on neurodegenerative disease and certain adiposity-associated cancers is under investigation. III. Side Effects and Mitigating Muscle Loss Concerns Common and Rare Side Effects The vast majority of side effects are Gastrointestinal and highest during the initial dose escalation: Nausea: Most common, but typically resolves over time. Management includes smaller, more frequent meals and temporarily lower-fat diets.Constipation: Persistent and requires active management with fiber and potentially laxatives.Rare Risks: Pancreatitis is a common concern but has shown no increased incidence compared to placebo in trials. Gallstone development is linked to rapid weight loss by any mechanism, including bariatric surgery. Muscle Mass Loss: Hype vs. Data The concern that these agents cause a unique, disproportionate amount of skeletal muscle loss is largely overblown hype. Initial Subgroup Analysis: Early analysis of Semaglutide trials suggested a higher proportion of fat-free mass loss (around 38%) than expected (25%). This was often cited as evidence of muscle catabolism.Physiological Reality: Experts suggest that much of the observed fat-free mass loss includes fluid shifts (glycogen, water) rather than pure skeletal muscle. Tirzepatide trials showed fat-free mass loss closer to the expected 25%.Muscle Quality Improves: Studies like SEMI-LEAN have shown that in patients with sarcopenia/obesity, muscle function (quality) actually improves despite some lean mass loss.Mitigation: The solution to minimizing any proportional muscle loss is simple: resistance training (2-3 days per week) and high protein intake (1.0 to 1.2 g/kg of body weight). Exercise is the primary controller here, minimizing the effect of the agents on the muscle compartment. IV. Access, Cost, and Future Outlook The Biggest Hurdle: Cost The primary barrier to access remains cost, with list prices for branded medications often exceeding $1,000 per month, despite lower net costs for manufacturers.18 Insurance approval often requires complex Prior Authorization (PA) processes, which overwhelm standard primary care practices. The Role of Compounding and Older Medications Compounded Versions: Compounded versions are cheaper but lack safety and efficacy data from controlled trials. There are risks associated with the source and purity of the active pharmaceutical ingredient.19Older Medications: Older anti-obesity medications (e.g., Phentermine/Topiramate) still have a role, offering proven efficacy (though less potent) and significantly lower cost, serving as a bridge until GLP-1 prices decline.Future Trend: Prices are expected to drop significantly in the next 5-10 years, making the FDA-approved versions more accessible and rendering compounded versions largely obsolete. Our Sponsors: * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com * Check out Factor: https://factormeals.com/bbm50off * Check out Quince: https://quince.com/BBM * Check out Rosetta Stone and use my code TODAY for a great deal: https://www.rosettastone.com Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    1h 26m
  6. Episode #376: Cycle Syncing, Cardio Myths, and Iron Deficiency: A Barbell Medicine Review of Diary of a CEO's Viral Claims

    NOV 28

    Episode #376: Cycle Syncing, Cardio Myths, and Iron Deficiency: A Barbell Medicine Review of Diary of a CEO's Viral Claims

    Cycle Syncing, Cardio Myths, and Iron Deficiency: A Barbell Medicine Review of Viral ClaimsEpisode Summary: Debunking Women's Health Claims and Setting Optimal Targets In this in-depth episode, Dr. Jordan Feigenbaum, joined by Dr. Lauren Colenso-Semple and Dr. Austin Baraki, breaks down the viral women's health claims made on a popular podcast, separating misleading mechanistic theory from actionable, evidence-based advice. They tackle three major topics: the idea that Cycle Syncing is necessary for performance (spoiler: it's not); the confused messaging surrounding HIIT and Zone 2 cardio (consistency is key); and a critical discussion on Iron Deficiency, clarifying why standard lab cutoffs for ferritin are too low and why treating to an optimal target (greater than or equal to 50 ng/mL) is essential for managing fatigue and optimizing exercise performance in women. ⏱️ Episode Timestamps 1:29 I. Cycle Syncing: The Claim and the Mechanistic Logic18:54 II. Conditioning Confusion: High Intensity, Zone 2, and Zone Definitions21:10 Polarized vs. Pyramidal Training (Context)47:08 III. Iron Deficiency: Normalizing Low Ferritin51:52 Evidence Review: Setting Accurate Ferritin Cutoffs ⭐ Get More Value: Exclusive Content and Resources Connect with Dr. Lauren Colenso-Semple: @drlaurencs1 Want to support the show and get early, ad-free access to all episodes plus exclusive bonus content? Subscribe to Barbell Medicine Plus and get ad-free listening, product discounts, and more. Try it free for 30-days. Unsure which training plan is right for you? Take the free Barbell Medicine Template Quiz to be matched with the ideal program for your goals and experience level. For media, support, or general questions, please contact us at support@barbellmedicine.com I. Cycle Syncing: Why Consistency Trumps Hormone Status The Problem with Mechanistic Reductionism The viral claim that women must systematically adjust their training volume and intensity based on fluctuating hormones (estrogen and progesterone) to optimize performance or avoid harm is based on a reductionist and largely unproven hypothesis. While hormone changes are real, relying solely on mechanistic data (what happens in isolated cells or textbook diagrams) is insufficient, as the complex, interactive nature of human physiology often overrides these single-factor effects. Dr. Feigenbaum and Dr. Colenso-Semple clarify that no reliable human evidence supports the idea that cycle syncing leads to superior athletic performance or adaptation. The fundamental flaw in the advice is that it confuses a plausible mechanism with a meaningful outcome. Harm Assessment: The Cost of Inconsistency The primary harm in cycle syncing is that it leads to missed training opportunities. Adaptation is driven by consistent training load (mechanotransduction), not a temporary hormone profile. Planning to proactively reduce training intensity or volume based on an unproven hormone schedule is detrimental to long-term strength and endurance gains. Training modifications should be reactive—if a person genuinely feels symptoms of fatigue, pain, or discomfort on a given day (regardless of their cycle status), they should adjust or skip the workout. The advice to only exercise or train hard when you "feel awesome" is inconsistent with the reality of progressive training and often sets unrealistic expectations. II. Conditioning Confusion: Context is Everything Debunking Zone 2 and HIIT Extremism The hosts address the confusing and contradictory advice regarding high-intensity interval training (HIIT) and Zone 2 cardio, particularly the claim that Zone 2 is "bro science" and should be avoided. The issue lies in a lack of context. The discussion on polarized (80/20) versus pyramidal training only becomes relevant for high-volume endurance athletes (those training for 10+ hours per week) where managing fatigue via intensity distribution is critical. For the general population—the vast majority of people consuming the viral content—the goal is simple: consistency. Adhering to the minimum physical activity guidelines (150 minutes of moderate or 75 minutes of vigorous activity per week) is the priority. For this audience, almost any combination of volume and intensity works, as long as it is challenging enough and sustainable. The complex debate over intensity distribution is entirely non-actionable for people simply trying to start or maintain an exercise habit. The advice was non-actionable because it: Used incorrect zone definitions ("Zone 1 is sitting around").Failed to integrate high-load resistance training into the cardio recommendation.Ignored the relationship between training frequency, volume, and total training load. III. Iron Deficiency: Treating to Optimal Physiology Normalizing Deficiency: The Problem with Lab Cutoffs Dr. Baraki addresses the critical issue of Iron Deficiency, emphasizing that many standard laboratory cutoffs for ferritin are misleadingly low. Labs often set the lower limit of "normal" (e.g., 12–15 ng/mL) based on population averages, not optimal physiology. This is problematic because upwards of 50% of young women in these samples may have completely depleted iron stores (non-anemic iron deficiency) due to menstrual blood loss and insufficient dietary intake. By accepting these low limits, the medical system is effectively normalizing deficiency. Optimal Ferritin Targets and Clinical Management The consequences of non-anemic iron deficiency include significant symptoms like fatigue, impaired exercise performance, and restless leg syndrome. The body strips iron from other tissues, including muscle, to prioritize red blood cell production, masking the deficiency until it reaches the end stage of anemia. Clinical guidelines are evolving, recognizing that higher ferritin levels are necessary for optimal health: General Target: A ferritin target of greater than or equal to 50 ng/mL is reasonable for most patients, especially those experiencing fatigue.Restless Leg Syndrome (RLS): A higher target of greater than or equal to 75 ng/mL may be necessary to address RLS, which is strongly linked to low iron stores in the brain.Treatment: Management often involves oral or IV iron supplementation to treat to this optimal target, while also investigating and treating the underlying causes of blood loss or malabsorption.The idea that we are accepting lower levels due to a "sicker population" is a misconception; in reality, cutoffs are being increased (e.g., American Gastroenterology Association: 45 ng/mL; American Society of Hematology: 50 ng/mL) as clinicians learn more about optimal physiology and the necessity of managing non-anemic iron deficiency. IV. Conclusion: Core Takeaways The goal of reviewing this viral content is to provide a vital filter for the public, differentiating between a simple mechanism and an outcome that truly matters to long-term health and training. Consistency is King: For health, find a training program you can adhere to consistently. Do not let fear of cortisol or unproven hormone matching keep you from moving your body.Lift Weights: If your goal is to get stronger and improve bone mineral density, you must lift weights.Address Fatigue: Do not overlook iron deficiency; address fatigue by targeting optimal ferritin levels. V. Citations https://pmc.ncbi.nlm.nih.gov/articles/PMC6120973/ https://pubmed.ncbi.nlm.nih.gov/30559681/ https://pubmed.ncbi.nlm.nih.gov/30559681/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6120973/ https://pubmed.ncbi.nlm.nih.gov/30559681/ https://www.nature.com/articles/s41467-025-63475-2  https://journals.lww.com/acsm-msse/pages/articleviewer.aspx?year=2025&issue=11000&article=00025&type=Fulltext https://onlinelibrary.wiley.com/doi/10.1155/tsm2/2008291  https://pubmed.ncbi.nlm.nih.gov/40010355/ https://pubmed.ncbi.nlm.nih.gov/33955140/ https://pubmed.ncbi.nlm.nih.gov/37084486/https://pubmed.ncbi.nlm.nih.gov/39576887/https://pmc.ncbi.nlm.nih.gov/articles/PMC7497427/https://pmc.ncbi.nlm.nih.gov/articles/PMC10300696/https://pubmed.ncbi.nlm.nih.gov/38066931/ Our Sponsors: * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com * Check out Factor: https://factormeals.com/bbm50off * Check out Quince: https://quince.com/BBM * Check out Rosetta Stone and use my code TODAY for a great deal: https://www.rosettastone.com Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    58 min
  7. Episode #375: The Sarcopenia Deep Dive- Why It's Not Just Muscle Loss (And How to Stop It)

    NOV 25

    Episode #375: The Sarcopenia Deep Dive- Why It's Not Just Muscle Loss (And How to Stop It)

    Episode Summary: Dynapenia, Motor Neurons, and the Firewall In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki redefine sarcopenia, shifting the focus from simple age-related muscle size loss (atrophy) to the more critical loss of muscle strength and power (dynapenia), a process that starts in the 40s. They explain the profound pathophysiology: sarcopenia is primarily a neurological event caused by the death of high-threshold motor neurons, leading to the selective loss of fast-twitch (Type II) muscle fibers. This explains why strength declines 3x faster than size. The hosts detail the modern diagnostic framework—prioritizing functional tests like the sit-to-stand test over late-stage mass measurements. They provide the definitive, evidence-based management plan: lifelong heavy resistance training is non-negotiable as it acts as a firewall against motor neuron death. The episode concludes with a debunking of common myths (e.g., "walking is enough," "muscle turns to fat," "lifting heavy is unsafe for the elderly") and practical advice on optimizing protein and creatine use to combat anabolic resistance. ⭐ Get More Value: Exclusive Content and Resources Want to support the show and get early, ad-free access to all episodes plus exclusive bonus content? Subscribe to Barbell Medicine Plus and get ad-free listening, product discounts, and more. Try it free for 30-days. Unsure which training plan is right for you? Take the free Barbell Medicine Template Quiz to be matched with the ideal program for your goals and experience level. For media, support, or general questions, please contact us at support@barbellmedicine.com Key Takeaways Sarcopenia is a Neurological Problem: The primary cause is the death of high-threshold alpha motor neurons, leading to the selective loss of fast-twitch (Type II) muscle fibers—the fibers responsible for power, speed, and fall prevention. This explains why strength (dynapenia) declines 3x faster than muscle size.Diagnosis Must Be Functional: Waiting for a doctor to diagnose sarcopenia via a muscle mass measurement (like a DEXA scan) is too late. Modern guidelines prioritize functional tests like grip strength and the sit-to-stand test as early warning signs, as muscle can be normal-sized but still dysfunctional.Resistance Training is the Firewall: Lifelong heavy resistance training slows motor neuron loss by 300% compared to the general population. Walking is not enough; only challenging resistance work sends the necessary signals (mechanotransduction) to preserve these critical motor neurons and Type II fibers.Nutrition for Treatment: For individuals diagnosed with sarcopenia, managing anabolic resistance is key. This requires attention to protein timing: consume a good dose of high-quality protein (rich in essential amino acids) at each meal. Supplementing with a third-party tested whey protein and 3-5g of creatine daily may be beneficial.Safety & Risk: The risk of injury from lifting weights, even heavy weights, in the elderly population is relatively low (2-4 injuries per 1,000 participation hours) and is greatly outweighed by the risk of immobility, falls, and subsequent complications. Episode Timestamps 0:00 Introduction: The Silent Epidemic and Dynapenia8:50 Defining Sarcopenia: Why Size Alone is Misleading (The Green Banana Analogy)17:37 Epidemiology and Sarcopenic Obesity23:39 Screening Tools: SARC-F, Sit-to-Stand Test, and When to Screen40:53 Pathophysiology: Why Sarcopenia is a Neurological Event42:28 Motor Neuron Death and Selective Type II Fiber Loss52:33 The Problem of Anabolic Resistance53:16 Management and Prevention Strategies57:20 Exercise Prescription (The "Why" and "How" of Resistance Training)1:10:44 Nutritional Strategy (Protein Boluses and Supplements)1:16:21 Sarcopenia Myths: Walking, Muscle Turning to Fat, and SafetySection I: Sarcopenia Redefined—A Failure of the Nervous SystemDynapenia and the Shift in Diagnostic Focus The episode establishes that sarcopenia must be understood as a problem of dynapenia (loss of strength and power) first, not just muscle size. Historically, the term, coined in 1989, focused on flesh poverty (Sarc-o-penia), but data quickly revealed that strength declines 3x faster than muscle mass. Old guidelines prioritized size, leading to a paradox: people with normal-sized muscles were still experiencing falls and fractures. The modern framework, driven by groups like the European Working Group, prioritizes functional outcomes. Waiting for a diagnosis via muscle size (like a DEXA scan measurement) means intervention is often too late. Muscle quality—the force produced per unit mass—declines dramatically due to neurological and cellular changes, even if the muscle maintains its volume through fat or water infiltration. The Pathophysiology: Alpha Motor Neuron Death The root cause of dynapenia is primarily neurogenic atrophy. Motor Neuron Loss: As individuals age, the high-threshold alpha motor neurons that innervate fast-twitch (Type II) muscle fibers begin to die (a process that can start in the 40s).Fiber Type Conversion: When a high-threshold neuron dies, a neighboring low-threshold (slow-twitch) neuron attempts to rescue the abandoned Type II muscle fiber. The fiber survives but is converted into a slow-twitch (Type I) fiber.Loss of Power: Since Type II fibers are responsible for rapid force production, the selective loss and conversion of these fibers means the individual loses speed and power, severely compromising the ability to perform activities like quickly rising from a chair or catching oneself during a trip (the righting reflex). This is why falls and subsequent hip fractures become common. Sarcopenic Obesity A particularly dangerous presentation is sarcopenic obesity, where a person carries both a significant amount of fat mass and poor muscle function. While individuals with obesity generally carry more lean mass, the fat infiltration (lipotoxicity) into the muscle tissue exacerbates anabolic resistance and insulin resistance, making the muscle dysfunctional and resistant to training and nutritional signals. This combination significantly compounds the risks of immobility and mortality. Section II: Management, Prevention, and Training Prescription Resistance Training is the Firewall The primary goal of intervention is prevention, as lost motor neurons cannot be regrown. Resistance training acts as a firewall against further motor neuron death. Mechanotransduction: Challenging resistance work sends necessary signals back to the motor neurons, signaling that the muscle fibers are still needed, slowing the rate of death.Evidence: Lifelong lifters show a neurogenic decline of only 0.35% per year, compared to the general population's decline of 1% per year—a 300% slower rate of loss. Walking is not enough to achieve this protective effect, as endurance athletes still show evidence of Type II fiber loss.Exercise Prescription: The Physical 401K For prevention, the goal is to fully fund the "physical 401K." This means exceeding the minimum physical activity guidelines: Resistance Training: At least twice a week, training all major muscle groups.Cardio: Aim for double the minimum (e.g., 300 minutes of moderate-to-vigorous activity per week).Progression: Individuals should build a big base of fitness, allowing them to be more aggressive with training load and resilient against co-morbidities later in life.For individuals with a diagnosis of sarcopenia (secondary prevention/treatment), the training emphasis shifts: Intensity is Non-Negotiable: Lifts must be challenging and performed with the intent of moving the load quickly to stimulate remaining Type II fibers.Start Lower, Progress Gradually: The population is more vulnerable to over-dosing due to chronic disuse. Start with a lower total volume but ensure progression is gradual and consistent.Type: While barbells are fine, machine-based training (e.g., leg press) may be a less intimidating entry point and can allow for higher training loads by mitigating the balance/fall risk of free weights.Section III: Nutrition, Supplements, and Myths Combating Anabolic Resistance with Protein Anabolic resistance—the reduced responsiveness of muscle to nutritional signals—is prevalent in sarcopenia. To overcome this, the focus should be on protein timing and quality: Total Intake: Aim for 1.2 to 1.6 grams of protein per kilogram of body weight per day (0.6 to 0.8g per pound).Protein Bolus: Ensure each meal contains a significant bolus of high-quality protein, rich in essential amino acids, to maximize the anabolic signal. This is critical for individuals whose appetite is often low.Supplements: A third-party tested whey protein supplement can be a useful tool for those who struggle to meet targets. Creatine (3-5g/day) is also strongly advised due to data supporting its benefit in improving lean mass and functional outcomes like the sit-to-stand test.Sarcopenia Myths Debunked (The Safety of Lifting) Myth: Walking is enough. Fact: No. Walking does not provide the challenging stimulus required to save high-threshold motor neurons and Type II fibers.Myth: Muscle turns to fat. Fact: No. Muscle and fat are distinct tissues. However, chronic disuse leads to fat infiltration into the muscle (lipotoxicity), which impairs function.Myth: It's unsafe to lift heavy after 60. Fact: The risk of injury from lifting weights in the elderly is relatively low (2-4 injuries per 1,000 participation hours) and is greatly outweighed by the high risk of immobility, falls, and subsequent complications caused by inactivity.Myth: GLP-1 agonists (Ozempic/Wegovy) cause sarcopenia. Fact: This is hysteria. Data does not support excessive muscle loss, and the benefit of reducing obesity-related risks far outweighs the low risk of muscle loss when coupled with resistance trai

    1h 28m
4.8
out of 5
1,179 Ratings

About

Podcast by Barbell Medicine

You Might Also Like